Update on Pfizer’s Phase 2 DAYLIGHT Study for Duchenne Muscular Dystrophy

May 7, 2024

Tuesday, May 7, 2024 – We at Jett Foundation are deeply saddened to learn about the devastating loss of a child participating in Pfizer’s Phase 2 DAYLIGHT clinical trial for Duchenne muscular dystrophy. Our hearts go out to the child’s family during this incredibly difficult time.

Please see Pfizer’s Community Letter to read more. We will continue to share any additional updates through our Duchenne News blog as the company investigates this matter.

Pfizer’s Community Letter

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open